ScreenerHero
STXShield Therapeutics plc
LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · shieldtherapeutics.com
4.900GBP+11.36%Mkt Cap: 67.24M $P/E: —

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap67.24M $
Enterprise Value84.04M $
Revenue (TTM)63.75M $
Gross Profit29.55M $
Net Income (TTM)-22.64M $
Revenue/Share0.0603 USD
Last Price4.900 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees61
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.53
PEG—
EV/EBITDA-6.67
EV/Revenue1.32
P/S1.05
P/B-4.64
EPS (TTM)-0.01
EPS (Forward)0.01
52W Range
3.70014% of range12.50
52W High12.50 GBP
52W Low3.700 GBP
Profitability
Gross Margin46.36%
Oper. Margin-15.07%
EBITDA Margin-19.76%
Profit Margin-35.52%
ROE117.10%
ROA-27.07%
Growth
Revenue Growth40.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.34M $
CapEx (TTM)384.78K $
FCF Margin12.56%
FCF Yield11.91%
Net Debt23.75M $
Net Debt/EBITDA-1.88
Balance Sheet
Debt/Equity-2.00
Current Ratio0.90
Quick Ratio0.67
Book Value/Sh-0.0106 GBP
Cash/Share0.0110 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)16.67 GBP
Upside (mean)+240.1%
Target Range12.00 GBP – 23.00 GBP
GBP12.00+240.1% to meanGBP23.00
# Analysts3
Ownership
Shares Out.1.07B
Float412.50M
Insiders61.75%
Institutions3.34%
Technical
SMA 505.585 (-12.3%)
SMA 2008.134 (-39.8%)
Beta1.72
S&P 52W Chg18.16%
Avg Vol (30d)3.04M
Avg Vol (10d)1.86M
Technical Indicators
RSI (14)50.3
MACD-0.4098
MACD Signal-0.5123
MACD Hist.+0.1025
BB Upper6.509 GBP
BB Middle4.678 GBP
BB Lower2.846 GBP
BB Width78.32%
ATR (14)0.4152 GBP
Vol Ratio (20d)2.05x